This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
4 Best-Performing Sector ETFs of June
by Sweta Killa
We have highlighted four top-performing ETFs from different sectors that have led the way in June.
Biotech ETFs Stage Solid Comeback at the Start of 2024
by Sweta Killa
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.
5 Least-Hurt Biotech ETFs of the Last Week
by Sanghamitra Saha
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
2 Sector ETFs Hovering Around a 52-Week High
by Sanghamitra Saha
We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.
5 Best Areas of Q3 of 2022 & Their Top ETFs
by Sanghamitra Saha
These ETF areas won in the third quarter of 2022.
Biotech & Crypto -- Best ETF Areas of Last Week
by Sanghamitra Saha
Biotech and cryptocurrency -- two ETF areas outperformed last week.
Biotech Wins Last Week: 5 Best ETFs
by Sweta Killa
The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.
The Zacks Analyst Blog Highlights BBC, CNCR XBI, BBP, and SBIO
by Zacks Equity Research
BBC, CNCR, XBI, BBP, and SBIO are part of Zacks top Analyst Blog.
5 ETFs Riding High on the Biotech Comeback
by Sweta Killa
Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.
Biotech ETFs That Outperformed Last Week
by Sweta Killa
Biotech ETFs was the biggest gainer last week.
Healthcare Emerges as Best Sector of Last Week: 5 Top ETFs
by Sanghamitra Saha
Wall Street was downbeat last week with all indexes in the red. Still, Healthcare sector emerged as a key winner last week.
The Zacks Analyst Blog Highlights: ITB, BBP, XSD, PRN, XRT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ITB, BBP, XSD, PRN, XRT
Beyond Clean Energy, 5 Sector ETFs Soaring to Record Highs
by Sweta Killa
As most corners of the market rallied on the slew of positive news, a few sectors scaled new highs. We have highlighted five ETFs from different sectors that hit all-time highs in the recent trading session.
4 ETFs to Play the Hot Events of Q4
by Sanghamitra Saha
The S&P 500 posted its best third-quarter gains since 2010 with an advancement of 8.5%. The gains could continue as the October-December period is normally gainful for the market.
Top-Performing ETFs of the Worst September Since 2011
by Sanghamitra Saha
After a superb August, September turned gloomy for Wall Street.
5 ETFs Shining Bright Amid September Selling
by Sweta Killa
The combination of lofty valuation, lack of additional fiscal stimulus package, election uncertainty and rising U.S.-China tensions weighed on investors' sentiment.
"Worst September in 18 Years"? 4 Sector ETFs Surviving Selloffs
by Sanghamitra Saha
After a superb August, September looks gloomy for Wall Street. Still,
A Guide to Biotech ETF Investing
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.
Biotech Tops in November: Best ETFs & Stocks
by Sweta Killa
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
Biotech ETFs Surge on a Flurry of Positive News
by Sweta Killa
The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.
Top and Flop ETFs So Far in Q2
by Sanghamitra Saha
The top ETF stories so far this second quarter linger around upbeat U.S. economic data points and the U.S.-China trade talks.
Biotechnology Market on a Tear: 5 ETFs in Spotlight
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
A Spread of Top-Ranked ETFs That Crushed the Market in Q1
by Sweta Killa
We are presenting a bunch of top performing ETFs of the first quarter with a solid Zacks ETF Rank #1 or 2 which are expected to outperform in the quarter ahead.
5 ETFs Shining With Green Returns & More Room to Run
by Sanghamitra Saha
These ETFs are in the green this year and are up for more gains.
Top ETF Stories of February
by Sanghamitra Saha
Inside the top ETF events of the month of February.